Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged it has received the supplemental new drug application (sNDA) for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients. The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022.
These Five Capital Region Biotechs Are The Fastest Growing in America
Published on :These Five Capital Region Biotechs Are The Fastest Growing in America December 5, 2018 In its 24th year, the Deloitte Technology Fast 500 is the premier technology awards program in [….]